Verrica Pharmaceuticals Engages Investors at Upcoming Event
Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), located in West Chester, is a significant player in the field of dermatology therapeutics, concentrating on innovative solutions for skin diseases that require medical attention. The Company has recently announced that Ted White, its President and CEO, will take part in an engaging fireside chat at the prestigious H.C. Wainwright 26th Annual Global Investment Conference in New York City.
Investment Conference Details
The H.C. Wainwright 26th Annual Global Investment Conference is set to take place from September 9-11, 2024, and is expected to attract top investors and analysts from the healthcare sector.
Event Information:
Date: Monday, September 9
Time: 1:30 PM ET
Location: New York, NY
How to Access the Live Webcast
Investors can watch a live webcast of the event, which will be available on the company's official website. A replay of the presentation will also be accessible shortly after the event, allowing those who cannot attend to gain valuable insights shared by Mr. White.
Verrica’s Innovative Dermatology Solutions
Verrica Pharmaceuticals is dedicated to addressing significant unmet needs in dermatology. Its flagship product, YCANTH (VP-102), is a revolutionary treatment that has received FDA approval for molluscum contagiosum, a common and highly contagious viral skin infection. This treatment primarily benefits children, positively impacting the lives of around 6 million individuals in the United States.
Future Developments at Verrica
Beyond YCANTH, Verrica is broadening its product pipeline with the development of VP-103, aimed at treating plantar warts. Additionally, the Company has entered into a global licensing agreement with Lytix Biopharma AS for VP-315, which targets non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.
Company Contact Information
For more information about the company’s initiatives and developments, you can reach out to the following contacts:
Terry Kohler
Chief Financial Officer
Email: tkohler@verrica.com
Kevin Gardner
LifeSci Advisors
Email: kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
Email: ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is Verrica Pharmaceuticals known for?
Verrica Pharmaceuticals specializes in dermatology therapeutics, focusing on the development of treatments for skin diseases that require medical intervention.
Who will represent Verrica at the H.C. Wainwright conference?
Ted White, the President and Chief Executive Officer, will be participating in a fireside chat at the event.
When is the H.C. Wainwright 26th Annual Global Investment Conference?
The conference is scheduled for September 9-11, 2024, with Verrica's session taking place on September 9 at 1:30 PM ET.
How can I access the live webcast of the conference?
The live webcast can be accessed via Verrica’s official website, and a replay will be available shortly after the presentation concludes.
What products does Verrica currently offer?
Verrica's prominent product is YCANTH (VP-102), which is FDA-approved for treating molluscum contagiosum, alongside ongoing developments in treatments for warts and skin cancers.